Evidence map›Paper›PMID 30701264›Full record

ArticleInternational journal of biopharmaceutical sciences2018

Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.

Colin M McGill, Timothy J Brown, Lindsey N Fisher, Sally J Gustafson, Kriya L Dunlap, Adam J Beck, Paul T Toran, David F Claxton, Brian M Barth

Open access · goldAbstract read
In one paragraph

Article in International journal of biopharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Alaska's Flora as a Treatment for Cancer.International journal of biopharmaceutical sciences · 2024
    Article
  2. The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.Journal of oncology research and therapy · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Colin M McGillDepartment of Chemistry, University of Alaska-Anchorage, Anchorage, AK 99508 USA.
Timothy J BrownDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA.
Lindsey N FisherDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA.
Sally J GustafsonDepartment of Chemistry and Biochemistry, University of Alaska-Fairbanks, Fairbanks, AK 99775.
Kriya L DunlapDepartment of Chemistry and Biochemistry, University of Alaska-Fairbanks, Fairbanks, AK 99775.
Adam J BeckDrug Discovery, Development, and Delivery Core, Penn State College of Medicine, Hershey, PA 17033 USA.
Paul T ToranDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824 USA.
David F ClaxtonDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA.
Brian M BarthDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA.
Penn State Milton S. Hershey Medical Center · USUniversity of Alaska Fairbanks · USUniversity of New Hampshire · USUniversity of Alaska Anchorage · US

Funding

The Administrative CoreP20GM103395 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI BRIAN M BARNES · 2012 to 2026
$66.1M
Tissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI LOUGHRAN, THOMAS P. · 2013 to 2024
$19.9M
Regulation of Ceramide-Based Therapeutics in Acute Myeloid LeukemiaK22CA190674 · NCI · UNIVERSITY OF NEW HAMPSHIRE · PI BARTH, BRIAN MICHAEL · 2016 to 2018
$485k
NCI NIH HHS K22 CA190674NCI NIH HHS P01 CA171983NIGMS NIH HHS P20 GM103395
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with limited treatment options. Inflammation is often a contributing factor to the development and progression of AML, and related diseases, and can potentiate therapy failure. Previously, we had identified anti-inflammatory roles and anti-AML efficacy for blueberry extracts. The present study extended these observations to determine that the polyphenol quercetin inhibited neutral sphingomyelinase (N-SMase) activity and exerted anti-AML efficacy. Moreover, quercetin was shown to exert combinatorial anti-AML efficacy with nanoliposomal ceramide. Overall, this demonstrated that quercetin could block the pro-inflammatory actions of N-SMase and augment the efficacy of anti-AML therapeutics, including ceramide-based therapeutics.

Indexed as

acute myeloid leukemiablueberrynanoliposomal ceramideneutral sphingomyelinasequercetin

Identifiers

PMID30701264
PMCPMC6349237
OpenAlexW2981639813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.